In HER2-amplified breast cancer, it has been reported that PTEN deletion causing MAPK hyperactivation is one such mutation41, and here we demonstrate that NF1 loss, ERBB2, and KRAS activating mutations, among others, also suffice. This evidence concerns the gene KRAS and breast cancer.